Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...

On Tuesday, the European Commission (EC) conditionally approved Merck & Co Inc’s (NYSE:MRK) Welireg (belzutifan), an oral ...

The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.

Fintel reports that on February 19, 2025, D. Boral Capital upgraded their outlook for CervoMed (NasdaqCM:CRVO) from Hold to ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), Merck’s oral ...

Dr David Sinclair, an expert described as a founding father of longevity research, has said the secrets to how you're ageing ...

Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a form of renal cell carcinoma (RCC) driven by a mostly inherited mutation.

Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented new data ...

Merck & Co’s – known as MSD outside of the US and Canada – Welireg (belzutifan) has been conditionally approved by the ...